{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:09:36Z","timestamp":1776287376220,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clbc.2023.02.004","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T12:52:22Z","timestamp":1676551942000},"page":"e194-e199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations"],"prefix":"10.1016","volume":"23","author":[{"given":"Maria G.","family":"Fencer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly A.","family":"Krupa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle C.","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry","family":"Grumet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas G.","family":"Eladoumikdachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shicha","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Kowzun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay B.","family":"Potdevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2023.02.004_bib0001","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2023.02.004_bib0002","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.annpat.2020.02.023","article-title":"Hereditary breast carcinomas pathologist's perspective","volume":"40","author":"Vincent-Salomon","year":"2020","journal-title":"Ann Pathol"},{"key":"10.1016\/j.clbc.2023.02.004_bib0003","first-page":"2113","article-title":"DNA repair genes implicated in triple negative familial non-BRCA1\/2 breast cancer predisposition","volume":"5","author":"Ollier","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clbc.2023.02.004_bib0004","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"New York Breast Cancer Study G. Breast and ovarian Cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.clbc.2023.02.004_bib0005","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/annonc\/mdv022","article-title":"Genetics of breast Cancer: a topic in evolution","volume":"26","author":"Shiovitz","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.02.004_bib0006","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral Breast Cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2023.02.004_bib0007","doi-asserted-by":"crossref","first-page":"e7161","DOI":"10.5867\/medwave.2018.04.7160","article-title":"Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women's BRCA carriers","volume":"18","author":"Honold","year":"2018","journal-title":"Medwave"},{"key":"10.1016\/j.clbc.2023.02.004_bib0008","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of Germline Mutations in 25 Cancer susceptibility genes in a sequential series of patients with breast Cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.02.004_bib0009","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1245\/s10434-019-08191-0","article-title":"Radiographic surveillance of patients with Non-BRCA1\/2 Pathogenic Variants","volume":"27","author":"Hudson","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2023.02.004_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/Familial High-risk assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clbc.2023.02.004_bib0011","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between Cancer predisposition testing panel genes and breast Cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2023.02.004_bib0012","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/jnci\/djaa023","article-title":"The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast Cancer from a clinical genetic testing cohort","volume":"112","author":"Hu","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2023.02.004_bib0013","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cam4.1376","article-title":"Gene panel testing of 5589 BRCA1\/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for hereditary breast and ovarian Cancer","volume":"7","author":"Hauke","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.clbc.2023.02.004_bib0014","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-10-3958","article-title":"Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer","volume":"71","author":"Casadei","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2023.02.004_bib0015","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S1470-2045(15)70142-7","article-title":"Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis","volume":"16","author":"Cybulski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2023.02.004_bib0016","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.02.004_bib0017","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in Cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clbc.2023.02.004_bib0018","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/gepi.21971","article-title":"Penetrance of ATM gene mutations in breast Cancer: a meta-analysis of different measures of risk","volume":"40","author":"Marabelli","year":"2016","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.clbc.2023.02.004_bib0019","first-page":"12","article-title":"The ATM gene in breast Cancer: its relevance in clinical practice","author":"Stucci","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.clbc.2023.02.004_bib0020","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.02.004_bib0021","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/jnci\/dji141","article-title":"Cancer risks and mortality in heterozygous ATM mutation carriers","volume":"97","author":"Thompson","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2023.02.004_bib0022","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1086\/302746","article-title":"ATM-heterozygous germline mutations contribute to breast Cancer-susceptibility","volume":"66","author":"Broeks","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clbc.2023.02.004_bib0023","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/cge.12710","article-title":"Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline","volume":"90","author":"van Os","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.clbc.2023.02.004_bib0024","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.2015.63.3594","article-title":"Increased risk for other Cancers in addition to Breast Cancer for CHEK2*1100delC Heterozygotes estimated from the Copenhagen general population study","volume":"34","author":"Naslund-Koch","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.02.004_bib0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ejhg.2013.85","article-title":"CHEK2*1100delC homozygosity in the Netherlands\u2013prevalence and risk of breast and lung cancer","volume":"22","author":"Huijts","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.clbc.2023.02.004_bib0026","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","article-title":"Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer","volume":"29","author":"Cybulski","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.02.004_bib0027","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40291-018-0344-x","article-title":"Association between CHEK2*1100delC and Breast Cancer: a systematic review and meta-analysis","volume":"22","author":"Liang","year":"2018","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.clbc.2023.02.004_bib0028","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/dna.2013.1970","article-title":"The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis","volume":"32","author":"Han","year":"2013","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.clbc.2023.02.004_bib0029","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/hmg\/ddi052","article-title":"Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population","volume":"14","author":"Shaag","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clbc.2023.02.004_bib0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/B:BREA.0000010697.49896.03","article-title":"Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers","volume":"83","author":"Broeks","year":"2004","journal-title":"Breast Cancer Res Treat"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:25:45Z","timestamp":1761513945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820923000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1526820923000344"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2023.02.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2023.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}